{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-027966","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.615736+00:00","generated_at":"2026-06-22T09:23:04.388206+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"C4 Therapeutics Q3 net loss widens to $32.0M; cash runway to end of 2024","bullets":["Net loss $32.0M ($0.65/diluted share) vs $24.7M ($0.51) in Q3 2021; revenue $6.8M vs $8.5M.","Cash, equivalents & marketable securities $366.0M at Sep 30, down from $451.5M at Dec 31, 2021; runway to end of 2024.","Phase 1/2 trials for CFT7455 (IKZF1/3 degrader in MM/NHL) and CFT8634 (BRD9 in synovial sarcoma) advancing dose escalation.","IND clearance for CFT1946 (BRAF-V600 degrader) in Sep; Phase 1/2 to initiate by year-end 2022.","Upcoming milestones: CFT8919 (EGFR L858R) IND-enabling activities to complete by year-end 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-027966","json":"https://secwatch.observer/filing/0001628280-22-027966.json","markdown":"https://secwatch.observer/filing/0001628280-22-027966.md","text":"https://secwatch.observer/filing/0001628280-22-027966.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828022027966/0001628280-22-027966-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828022027966/cccc-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:23:04.388206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"309260600e0123f5b7c6af4545bed2faaaf1abbd","claim":"C4 Therapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $6.8 million, net income $32.0 million, EPS $0.65.","evidence_excerpt":"will participate in a fireside chat at the Evercore ISI HealthCONx Conference. THIRD QUARTER 2022 FINANCIAL RESULTS Revenue: Total revenue for the third quarter of 2022 was $6.8 million, compared to $8.5 million for the third quarter of 2021. Total revenue reflects revenue recognized under collaboration agreements with Roche, Biogen, and Calico. Research and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828022027966/0001628280-22-027966-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$6.8 million"},{"label":"Net income","value":"$32.0 million"},{"label":"EPS","value":"$0.65"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}